STI-Pharm

ST Pharm is a leading South Korean contract development and manufacturing organization (CDMO) specializing in the production of oligonucleotides and mRNA-based therapeutics. Originally established as Samchully Pharm and later known as STI-Pharm, the company is now a key subsidiary of the Dong-A Socio Group. ST Pharm provides comprehensive services ranging from small molecule APIs to advanced genetic medicines, leveraging proprietary technologies like the SmartCap mRNA capping system. The company maintains a robust internal pipeline focused on high-unmet-need areas such as HIV and oncology, while serving as a global supplier for major pharmaceutical partners. Its state-of-the-art facilities in Ansan are among the largest oligonucleotide manufacturing sites in the world.